Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE │ TSX: ACB), the Canadian firm specifying the potential of cannabis globally, today announced that among the Company’s petroleum products has been approved to be used under Ireland’s brand new Medical Cannabis Access Programme (MCAP). Aurora’s High CBD Oil Drops received consent from the Irish government and have been added to some regulatory program by the Irish Minister of Health allowing importation, prescribing and distribution under the strategy and is thus far, one of just two products to acquire such approval.
Dr Shane Morris, Chief Product Officer in Aurora stated, “Aurora is pleased to be able to assist patients who are seeking treatment with high quality EU-GMP (good manufacturing practice) certified pharmaceutical-grade medical cannabis in Ireland. We are very proud to be one of the first approved suppliers of medical cannabis under the MCAP. We want to acknowledge the efforts made by many people, especially the patients and doctors who have campaigned for access to these medicines. We look forward to more of Aurora’s high-quality medicines being approved, so that more patients can benefit from the MCAP in Ireland. We will continue to work closely with all parties and state agencies to facilitate further availability.”
Under the new programme, a consultant can prescribe medical cannabis for patients under their care that have some of these medical conditions:
- Spasticity associated with multiple sclerosis
- Intractable nausea and vomiting related to chemotherapy
- Acute, refractory (treatment-resistant) epilepsy
The Medical Cannabis Access Programme was signed into legislation in June 2019 by Ireland’s Minister for Health, Simon Harris. The programme will ease access to cannabis-based medical goods in accord with laws and is scheduled to operate for five decades.
Headquartered at Edmonton, Alberta, Canada with financed capacity in excess of 625,000 kg per annum and earnings and operations in 25 nations across five continents, Aurora is one of the world’s biggest and major cannabis businesses. Aurora is vertically integrated and horizontally diversified across each key sector of the value chain, from centre engineering and style to both cannabis breeding and genetics study, cannabis and hemp manufacturing, derivatives, higher value-add merchandise development, home farming, retail and wholesale supply.
highly distinguished by its peers, Aurora has created a uniquely innovative, consistent and effective manufacturing approach, dependent on purpose-built facilities which incorporate leading-edge technology across all procedures, characterized by extensive automation and personalization, leading to the huge scale creation of high quality consistent item. Made to be replicable and scalable worldwide, our manufacturing facilities are intended to create cannabis at substantial scale, with higher quality, industry-leading yields, and low-per g production expenses. Every one of Aurora’s centers is constructed to fulfill European Union Good Manufacturing Practices (“EU GMP”) criteria ) Certification was awarded to Aurora’s first manufacturing facility in Mountain View County, the MedReleaf Markham centre, and its wholly owned European medical cannabis distributor Aurora Deutschland. All of Aurora facilities have been designed and constructed to the EU GMP standard.
Along with the organization’s rapid organic growth and strong implementation on tactical M&A, which thus far includes 17 wholly owned subsidiary businesses — MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco — Aurora is distinguished by its standing for a spouse and employer of choice in the worldwide cannabis sector, having spent in and established strategic partnerships with a variety of top innovators, such as: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (personal ), Evio Beauty Group (personal ), and Wagner Dimas (personal ).
Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and is a part of this S&P/TSX Composite Index.
to learn more about Aurora, please see our investor site, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release contains statements comprising particular “forward-looking information” within the meaning of applicable securities legislation (“forward-looking statements”). Forward-looking statements are often characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other comparable phrases, or statements that certain events or circumstances “may” or “will” happen. These forward-looking statements are just predictions. A variety of assumptions were utilized in drawing the conclusions or making the projections inside the forward-looking statements during this news release. Forward-looking statements are based upon the opinions, estimates and assumptions about direction in light of management’s experience and perception of historical trends, current conditions and anticipated developments in the date the statements are made, for example present and prospective market requirements, the present and future regulatory environment and prospective approvals and licenses. Forward-looking statements are subject to many different risks, uncertainties and other factors that management considers to be applicable and realistic in the circumstances might cause actual events, results, amount of activity, performance, prospects, chances or achievements to differ materially from those projected at the statements that are forward, such as general business and economic conditions, changes in legislation and regulations, product demandchanges in costs of commodities that are required, competition and other risks, uncertainties and factors set out under the heading “Risk Factors” from the organization’s yearly information form dated September 10, 2019 (the “AIF”) and filed with Canadian securities authorities which can be found on the organization’s issuer profile on SEDAR in www.sedar.com. The business cautions that the record of risks, uncertainties and other factors described from the AIF isn’t comprehensive and other factors may also adversely affect its consequences. Clients are advised to consider the risks, uncertainties and assumptions carefully in assessing the forward-looking statements and are cautioned to not place undue reliance on such advice. The business is under no obligation, and expressly disclaims any intention or obligation, to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as explicitly required by applicable securities legislation.